| Autor: |
Farshad Guirakhoo, Chang Yi Wang, Chwan-Chuen King King, Mary Kate Morris, Yu-Hsin Ho, Thomas P. Monath, Jennifer Cheng, Ming-Han Jiang, Michael Hellerstein, Kao-Pin Hwang, Yu-Rou Lan, Donald Gray Heppner, Tracy Kemp, Jian-Jong Liang, Sky Chen, Min-Sheng Wang, Po-Yen Chang, Feng Lin, Chun-Che Liao, Shuang Ding, Hui-Kai Kuo, Carl V. Hanson, Hsuan-Yu Shen, Huang-Ting Wu, Mei Mei Hu, Ya-Ting Yang, Hui-Jiing Yu, Yi-Ling Lin, Daphne Shen, Kuo-Liang Hou, Be-Sheng Kuo, Zhi Liu, Han Chen Chiu, Yu-Chi Chou, Hao-Yu Shih, Juin-Hua Huang, James Peng, Hope Liu |
| Rok vydání: |
2021 |
| Předmět: |
|
| DOI: |
10.21203/rs.3.rs-944205/v1 |
| Popis: |
SARS-CoV-2 breakthrough infection occurs due to waning immunity time-to-vaccine, to which the globally-dominant, highly-contagious Delta variant is behind the scene. In the primary 2-dose and booster series of clinical Phase-1 trial, UB-612 vaccine, which contains S1-RBD and synthetic Th/CTL peptide pool for activation of humoral and T-cell immunity, induces substantial, prolonged viral-neutralizing antibodies that goes parallel with a long-lasting T-cell immunity; and a booster (3rd ) dose can prompt recall of memory immunity to induce profound, striking antibodies with the highest level of 50% viral-neutralizing GMT titers against live Delta variant reported for any vaccine. The unique design of S1-RBD only plus multitope T-cell peptides may have underpinned UB-612’s potent anti-Delta effect, while the other full S protein-based vaccines are affected additionally by mutations in the N-terminal domain sequence which contains additional neutralizing epitopes. UB-612, safe and well-tolerated, could be effective for boosting other vaccine platforms that have shown modest homologous boosting. [Funded by United Biomedical Inc., Asia; ClinicalTrials.gov ID: NCT04967742 and NCT04545749] |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
